Cancer Plan Annual Revisions

The Florida Cancer Control and Research Advisory Council (CCRAB) is considering several revisions to the Florida Cancer Plan. These proposed revisions were communicated following the CCRAB meeting on May 21, 2021 and would update screening guidelines included in two Cancer Plan Goals to reflect recent changes made by the USPSTF.

The 30-day consideration period for CCRAB Council Members to provide comments will begin on Monday, August 16, 2021. Comments must be submitted to [email protected] by 5:00 PM (ET) on Wednesday, September 15, 2021. Revisions will be discussed and approved by the Council during the CCRAB meeting on Friday, September 17, 2021.

 

Lung Cancer Screening Goal/Objective:

Proposed revision changes age range and smoking history to match U.S. Preventive Services Task Force (USPSTF) recommendation update.

Goal 10: Reduce lung cancer mortality through early detection of lung cancer in Floridians.

Lung cancer is the most frequently diagnosed cancer in Florida and is also the number one most lethal cancer in Florida. One of the greater challenges in diagnosing lung cancer is that patients often present with advanced stage disease that cannot be cured. In 2011, we learned from the National Lung Screening Trial that current and former heavy tobacco smokers had a 15-20% lower risk of dying from lung cancer with annual low-dose computed tomography (LDCT) scans compared to annual chest X-ray exams. Moreover, these LDCT-visible lung cancers were diagnosed at earlier and more limited stages when curative interventions are possible. Consequently, the USPSTF in 2013 2021 recommended annual screening for lung cancer with LDCT in adults aged 55 50 to 80 years who have a 30 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Given the problem of advanced stage lung cancer in Florida, our goal is to use annual lung cancer screening in Floridians at higher risk for lung cancer to catch the tumors when they are small and haven’t spread, thus creating opportunities for curative interventions.

Objective 10.2: By 2025, identify or develop a surveillance method that measures the percentage Florida adults aged 55 50 to 80 years old who are at higher risk for lung cancer and who have undergone annual lung cancer screenings.

 
Colorectal Cancer Screening Goal/Objective:

Proposed revision changes age range to match U.S. Preventive Services Task Force (USPSTF) recommendation update.

 Objective 12.2: By 2025, increase the percentage of Floridians aged 50 45 to 75 years old who have fully met the US Preventive Services Task Force (USPSTF) recommendation for colorectal cancer screening from 70.4% (Baseline, 2018 BRFSS) to 80% or higher.

Additional Information:

Plan for Making Changes to the Florida Cancer Plan

Florida Cancer Plan Goals, Objectives and Strategies Selection Criteria 

The Florida Cancer Control and Research Advisory Council (CCRAB) is considering several revisions to the Florida Cancer Plan. These proposed revisions were presented and discussed during the CCRAB meeting on October 23, 2020.

The 30-day consideration period for CCRAB Council Members to provide comments and approval will begin on Monday, November 16, 2020. Comments must be submitted to [email protected] by 5:00 PM (ET) on Wednesday, December 16, 2020.

Radon Goal/Objectives:

Proposed revisions change baselines for objectives 9.1, 9.2 and 9.4 based on new data; updates annual percentage increases for each objective based on the new baseline data.

Objective 9.1: By 2025, increase the annual number of homes measured for radon from 11,570 16,940 to 14,080 25,420 homes (increase by 4 7% annually).

Objective 9.2: By 2025, increase the annual number of homes mitigated for radon from 1,190 1,950 to 1,440 2,600 homes (increase by 4 5% annually).

Objective 9.4: By 2025, increase the number of Florida real estate transactions that include radon testing from 6,500 8,080 to 7,500 10,220 in five years (increase by 3 4% annually).

Prostate Cancer Goal:

Proposed revision rationale: Advanced disease implies disease extension either regionally to lymph nodes or distant metastases to bone. Options for treatment are palliative for metastatic or advanced disease. Aggressive disease (Gleason 7 or greater) more appropriately describes contained, high-risk, but treatable and potentially curable disease if diagnosed early through proper screening. Sophisticated supplemental PSA testing including serum 4K is an algorithm calculating risk for “aggressive” disease and is used to additionally guide the prostate biopsy decision.

Goal 13: Reduce prostate cancer mortality in Florida men through early detection of advanced disease at high risk for aggressive prostate cancer through screening and early detection.

Hepatitis C Virus (HCV) Goal/Objective:

Proposed revision changes age range to match U.S. Preventive Services Task Force (USPSTF) recommendation update.

Objective 14.1: By 2025, identify or develop a surveillance method that measures the percentage of Floridians born between 1945 and 1965 aged 18 to 79 years old who were offered and received HCV testing.

 

Additional Information:

Plan for Making Changes to the Florida Cancer Plan

Florida Cancer Plan Goals, Objectives and Strategies Selection Criteria